Spotlight on Science
Abstracts selected by the Annual Meeting Organizing Committee with assistance from the National Academy of Clinical Biochemistry for their quality and the importance of their research in one of three topic areas will be presented in dynamic sessions held on three consecutive afternoons. In each 15-minute presentation and 5-minute question-and-answer session, attendees will hear the best of cutting-edge research, a hallmark of the AACC Annual Meeting.
Session
Chronic Diseases and Clinical Outcomes
July 29, 2:30–5 p.m.
Review of Ordering Practices for Procalcitonin From a Critical Care Unit
Douglas Stickle, PhD, BS, MS, DABCC
Thomas Jefferson University
Jefferson Medical College, Philadelphia
Determination of Cardiac Troponin With a Single-Molecule High Sensitivity Assay and Outcomes in Patients With Stable Coronary Artery Disease: Analysis From PROVE IT-TIMI 22
Petr Jarolim, MD, PhD
Brigham and Women’s Hospital, Boston
Procalcitonin as a Biomarker of Bacterial Infection in Acute Liver Failure
Jody A. Balko, MS
University of Texas Southwestern
Medical Center, Dallas
Measurement of Galectin-3 Levels with the Architect Assay in Patients with Systolic Heart Failure
Damien Gruson, PharmD
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Plasma Levels of D-Dimer as an Indicator of Severity and Mortality in Acute Stroke: Application of Biochip Array Kit
Craig Ledgerwood, PhD
Randox Laboratories Limited
Crumlim, Northern Ireland
Performance of a High-Sensitivity Cardiac Troponin I Assay in Patients With Non-ST-Elevation Acute Coronary Syndrome
Petr Jarolim, MD, PhD
Brigham and Women's Hospital, Boston
Absence of Association Between Serum Folate and the Development of Preeclampsia in Women Exposed to Folic Acid Supplementation and Food Fortification
Sebastien Theruault, MD
Universite Laval, Quebec City, Canada
Session
Personalized and Translational Medicine
July 30, 2:30–5 p.m.
The CYP1A2*1D Polymorphism Has a Significant Impact on Olanzapine Serum Concentrations
Werner Steimer, MD, FACB
Technical University of Munich
Munich, Germany
Rapid and Cost Effective Measurement of Circulating Cell Free Graft DNA for the Early Detection of Liver Transplant
Ekkehard Schuetz, MD
University of Göttingen
Göttingen, Germany
The Association of a Single Nucleotide Polymorphism in FSHR Gene With Adverse Radiotherapeutic Effects in Prostate Cancer Patients
Zengliu Su, MD
Medical University of South Carolina
Charleston
Biological Variation and Quality Specifications for 38 Biochemical Markers in a Pediatric Population
Victoria Bevilacqua, BS
The Hospital for Sick Children
Toronto, Canada
Establishing Analytical Methods for CYP2D6 Genotyping and Measurement of Tamoxifen and Its Metabolites for the Assessment of Tamoxifen Therapy
Lie Fu, PhD, DABCC, FACB
Sunnybrook Health Science Center
Toronto, Canada
PSA Enzymatic Activity: A New Biomarker for Assessing Prostate Cancer Aggressiveness
Dimitra Georganopoulou, PhD
OHMX Corporation, Evanston, Ill.
A Highly Sensitive and Specific Method for Characterization of Circulating Tumor Cell Subtypes in Breast Cancer Patients
Lori Millner, PhD
University of Louisville Health
Sciences Center, Louisville, Ky.
Session
Clinical Implementation of Emerging Technologies
July 31, 2:30–5 p.m.
On-Site Colorimetric Detection of Sweat Chloride Ion for Diagnosing Cystic Fibrosis
Xuan Mu, PhD
Peking Union Medical College
Beijing, China
Prostate Proteins Glycosylation Profile and Its Potential as a Diagnostic Biomarker for Prostate Cancer
Joris Delanghe, PhD, MD
University Hospital Ghent
Ghent, Belgium
Use of Urinary Neutrophil Gelatinase-Associated Lipocalin in the Diagnosis of Acute Kidney Injury Among Stroke Patients. Is It Time to Rethink Our Diagnostic Criteria for AKI?
Konstantinos Makris, PhD
KAT General Hospital, Athens, Greece
Identification of Models to Predict Sepsis in Emergency Department Patients
Frances Cate, MD
Vanderbilt University, Nashville, Tenn.
Predicting Iron Deficiency From Complete Blood Counts Using a Mathematical Model of RBC Maturation
Harsh Patel, BS
Massachusetts General Hospital, Boston
BCMA Is a Novel Serum Biomarker for Diagnosis and Prognosis of Multiple Myeloma
Haiming Chen, MD, PhD
Institute for Myeloma and Bone Cancer Research
West Hollywood, Calif.
Identification of Novel Biomarkers of Hemorrhagic Stroke by Integrating Bioinformatic and Mass Spectrometry-Based Approaches
Eduardo Martinez, PhD
Mt. Sinai Hospital, Toronto, Canada